News

In total, 6.4% of those with intellectual disability achieved seizure freedom and 37.5% had at least a 50% responder rate after treatment with perampanel.

Prespecified and post hoc analyses explored the heterogeneity of disease at baseline, with meaningful treatment effect indicated in a subset of patients with less severe ALS.

While typically thought of as a disease that affects younger populations, Rebecca O’Dwyer, MD, stressed the importance and nuances of caring for older adults with epilepsy.

The scientific director at the Dravet Syndrome Foundation discussed a recent survey asking caregivers about the experiences of patients with DS following COVID-19 vaccination. [WATCH TIME: 3 minutes]

Findings presented at AES 2021 included data from children with tuberous sclerosis complex and drug refractory epilepsy who were not candidates for epilepsy surgery.

Four out of 6 patients with CDKL5 deficiency disorder and comorbid Lennox-Gastaut syndrome had a decrease in frequency of major motor seizures when treated with ganaxolone.

Half of the patients who were on a flexible, longer-term Cognitive Behavioral Therapy-informed psychotherapy treatment schedule demonstrated improvements in seizure frequency by more than 50%.

At the 12-month mark, more than 64% of patients had remained on perampanel, with an overall mean retention time of 10.8 months.

The clinical psychologist at Cleveland Clinic discussed the potential of using cognitive behavioral therapy for treatment of psychogenic non-epileptic seizures on cognitive behavioral therapy. [WATCH TIME: 3 minutes]

Approval permits the initiation of a phase 2 study to ascertain the efficacy of intranasal potentiated oxytocin in patients with chronic migraine.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Findings were presented at AES 2021, with 56.7% of patients reporting a 50% or greater reduction in seizure frequency.

Data suggest that roughly 1 in 100 patients hospitalized with COVID-19 infection will develop central nervous system complications.

Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]

The investigational ZZ Biotech treatment was previously evaluated in patients with acute ischemic stroke, with exploratory analyses showing a trend towards lower hemorrhage rate.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

More than two-thirds of patients who received prednisolone after showing no response to vigabatrin demonstrated complete electroclinical response at 2 weeks, with most sustaining response at 6 weeks.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed the positive trends within the Alzheimer drug development space. [WATCH TIME: 2 minutes]

After previously showing proof-of-concept in a phase 2 setting, investigators will continue to evaluate efficacy and safety of apitegromab, potentially the first muscle-directed therapy for patients with SMA.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Szperka, MD, MSCE.

The approval expands the devices existing indications for medication-refractory essential tremor and tremor-dominant Parkinson disease.

There was a statistically significant difference in epileptic seizure frequency means across baseline and the 6- and 12-month follow-up visits.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the positive feedback from patients when discussing telehealth. [WATCH TIME: 4 minutes]

The FDA-approved preventive therapy for migraine was well-tolerated, with low dropout rates, and showed sustained clinically meaningful outcomes across a 2-year stretch.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts. [WATCH TIME: 3 minutes]

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.